| May 19, 2022
Node-Negative: Chemotherapy Benefit
Updated NCCN Guidelines® from the National Comprehensive Cancer Network® (NCCN®) underscore the unique advantage of the 21-gene (Oncotype DX) test as the only preferred multi-gene test to determine chemotherapy benefit for patients with node-negative early-stage breast cancer. (See page BINV-6 in the Guidelines.)
Node-Positive: Inclusion in the Algorithm
Additionally, the NCCN Guidelines elevated multi-gene assays, including the 21-gene (Oncotype DX) test into the algorithm to consider for assessing prognosis and determining chemotherapy benefit for patients with micrometastases and 1–3 positive nodes. (See page BINV-7 in the Guidelines.)
-
NODE-POSITIVE
-
NODE-NEGATIVE
Tab Item Conten 2
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer Systemic Adjuvant Treatment: Hormone Receptor-Positive, HER2-Negative Disease
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed commodo dictum metus, sit amet ullamcorper tellus bibendum non. Praesent a arcu et sem ullamcorper hendrerit at tempus turpis. Suspendisse tincidunt ornare sapien, nec blandit est venenatis vel. Nulla malesuada malesuada sapien, at aliquam sapien eleifend quis. Mauris eu gravida lacus, at tincidunt mauris. In dui mauris, luctus non elit eget, rutrum tempor est. Morbi purus ligula, commodo nec semper ut, interdum at libero. Donec pulvinar nisl a augue pharetra pretium.
Node-Negative: Chemotherapy Benefit
Read the official press release on the significance of these updated guidelines.
Backed by clinical data
The landmark TAILORx trial results provide definitive answers
-
References